Yarrow Bioscience (YARW) EPS (Basic) Growth (3y) (2020 - 2026)
Powered by 
Analysis
Yarrow Bioscience (YARW) EPS (Basic) Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 12.25% |
| 10 | Yarrow Bioscience | 25.25 Mn | 2.33 Mn | - | 71.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.64% |
| Mar 31, 2026 | 63.52% |
| Jun 30, 2025 | 2.75% |
| Mar 31, 2025 | -63.78% |
| Dec 31, 2024 | -7.89% |
| Sep 30, 2024 | 11.30% |
| Jun 30, 2024 | 17.09% |
| Mar 31, 2024 | 29.60% |
| Dec 31, 2023 | 5.56% |
| Sep 30, 2023 | -138.79% |
| Jun 30, 2023 | -36.51% |
| Mar 31, 2023 | -22.20% |
| Dec 31, 2022 | -7.20% |
| Sep 30, 2022 | 0.79% |
| Jun 30, 2022 | 4.53% |
| Mar 31, 2022 | 28.94% |
| Dec 31, 2021 | 56.45% |
| Sep 30, 2021 | 9.78% |
| Jun 30, 2021 | -2.18% |
| Mar 31, 2021 | 16.40% |